Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEU-411 phase 2 trial in early LRRK2-driven Parkinson's disease
MOH_2026-02-11_015652Phase 2Recruiting
- Sponsor
- Neuron23
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NEU-411 in Parkinson's disease (PD) (3 arms), sponsored by Neuron23. Started Feb 2026; status: recruiting.
02
Drugs
NEU-411
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on MOH_2026-02-11_015652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-02-11_015652.